[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nets\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nets":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,61,90,118],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":36,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":60},"100549997","phase-1-phase-i-trial-to-determine-the-dose-and-evaluate-the-pk-and-safety-of-lutetium-lu-177-edotreotide-therapy-in-pediatric-participants-with-sstr-positive-tumors-100549997",false,"NCT06441331","Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors","A Multicenter, Open-label, Interventional Phase I Trial to Determine the Dose and Evaluate the Pharmacokinetics (PK) and Safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as Monotherapy or Following Standard of Care (SoC) for the Treatment of Somatostatin Receptor-positive Tumors in the Pediatric Population (KinLET).","KinLET","Key Inclusion Criteria:\n\n* Participants aged ≥ 2 years and \\\u003C 18 years\n* Confirmed diagnosis somatostatin receptor-positive (SSTR-positive) disease.\n* Tumor which is relapsed or is refractory to at least one line of previous therapy\n* Positive SSTR protein expression confirmed by immunohistochemistry of a tumor histology sample\n* Radioactivity uptake within the primary tumor or metastatic tumor sites measured by locally available SRIs ( 111In-based, 99mTc-based, or 68Ga-based SSTR single-photon emission computed tomography (SPECT)\u002F computed tomography (CT) or positron emission tomography (PET)\u002FCT imaging, which is higher than the liver uptake)\n* Participants must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria, excluding alopecia, stable treated electrolyte abnormalities on replacement and stable treated hypothyroidism) of all prior treatment modality prior to entering this trial\n* In case of sequential treatment followed by SoC or prior therapy, washout period applies before starting targeted RPT\n\nScreening Consent Participant\u002Flegal guardian is willing to sign a screening consent. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.\n\nKey Exclusion Criteria:\n\n* Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA\u002FEdotreotide, or excipients\n* Previous history of acute leukemia unless in remission for at least two years\n* Extensive bone\u002Fbone marrow involvement as per Investigator's judgement unless peripheral blood stem cells (PBSC) are available at a minimum of 2.5x106 CD34+ cells\u002Fkg\n* Patients who have received previous systemic targeted RPT\n* Previous treatment with metaiodobenzyl guanidine (MIBG) if the predicted overall exposure is expected to exceed 2 Gy (gray) to the bone marrow or 23 Gy to the kidney.\n* Previous treatment with external beam radiation therapy (EBRT) if the predicted overall exposure is expected to exceed more than 2 Gy to the bone marrow or 23 Gy to the kidney.\n* Previous treatment with oncologic immune vaccine or CAR-T cell therapy\n* Bulky disease in the CNS\n* Presence of severe renal, hepatic, electrolyte, cardiovascular, or hematological dysfunction\n* Participants who have received a live-attenuated vaccine up to four weeks prior to enrolment\n* Pregnant or breastfeeding women.\n* Other known malignancies.\n* Serious non-malignant disease.","ALL","24 Months","18 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to \\\u003C18 years of age with somatostatin receptor (SSTR)-positive tumors.",[28,29,30,31,32,33,34,35],"Somatostatin Receptor Positive","NETs","Lymphoma","Solid Tumor","CNS Tumors","Rhabdomyosarcoma","Peripheral Primitive Neuroectodermal Tumor","GIST",[37,38,39,30,40,41,42,43,44,45,46,47],"Pediatric","CNS tumors","Solid tumors","Somatostatin Receptor (SSTR)-positive Tumors","Lutetium Lu 177 Edotreotide","Targeted RPT","ITM","GEP-NET","Neuroendocrine tumors","Radiopharmaceutical Therapy","Childhood","RECRUITING","2026-04-27",{"date":51,"type":52},"2026-05-01","ACTUAL",{"date":54,"type":52},"2025-09-26",{"date":56,"type":22},"2034-04",{"name":58,"class":59},"ITM Solucin GmbH","INDUSTRY",5,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":71,"phases":4,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100613868","endoscopic-ultrasound-guided-radiofrequency-ablation-for-upper-gastrointestinal-tract-lesions-100613868","NCT07272187","Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions","Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions - a Prospective Study","EURAGIL","Inclusion Criteria:\n\n* Patients with one or more lesions amendable to undergo EUS-RFA\n\n  * Insulinomas ≤ 25 mm confirmed by a 72-h fasting test, cross-sectional scanning, and a biopsy with low Ki67 index (\\\u003C10%)\n  * Non-functional pNEN lesions between 10-20 mm and growing, confirmed by a biopsy with low Ki67 index (\\\u003C10%), or larger pNEN lesions in patients who are not candidates for surgical treatment\n  * Unilateral APA with benign characteristics on non-contrast enhanced CT located in the left adrenal and confirmed lateralization on AVS\n\n    * Adult habile patients\n    * Signed informed consent\n\nExclusion Criteria:\n\n* Severe multimorbidity (ASA score ≥ IV or ECOG performance score ≥ 4)\n\n  * Uncorrected coagulopathy (INR \\>1.8 or thrombocyte count \\\u003C 50 mia\u002FL)\n  * Pregnancy\n  * Metastatic malignancy with expected remaining life expectancy \\\u003C 3 years\n  * Stenosis in upper GI tract or altered anatomy (e.g. previous gastrectomy) preventing the passage of an echoendoscope",{"count":70,"type":22},138,"OBSERVATIONAL","The goal of this observational study is to evaluate the long-term clinical effectiveness of EUS-RFA and quality of life in patients with pancreatic or adrenal tumors recieving EUS-RFA.\n\nPrimary Objectives:\n\n* Clinical effectiveness: To evaluate the proportion of included patients who show doc-umented improvement in their clinical symptoms and biochemical parameters (blood test results) over time.\n* Patient satisfaction: To assess patient satisfaction with the procedure and subsequent disease-related quality of life, measured using validated questionnaires.\n\nSecondary Objectives:\n\n* Safety: To determine the proportion of treated patients who experience complications, as defined by the AGREE classification, within 30 days after the procedure.\n* Technical success: To assess the proportion of included patients in whom the EUS-RFA procedure can be successfully completed.\n\nExploratory Objectives:\n\n• To identify factors associated with adverse events and factors related to clinical success or lack there of.\n\nThe study is observational. All participant will receive EUS-RFA as part of their standard clinical care.\n\nParticipants will:\n\n* Undergo EUS-RFA, in which a fine needle is guided into the tumor using an endo-scope and ultrasound imaging. Radiofrequency energy is applied through the needle to heat and destroy tumor cells while protecting the surrounding tissue.\n* Have follow-up visits including blood tests, imaging scans, and clinical evaluations at regular intervals for up to 5 years after treatment.\n* Complete validated questionnaires about satisfaction and quality of life.\n\nThe study will include approximately 138 patients recruited between 2025 and 2035 from two Danish hospital departments (Herlev and Gentofte Hospital and Rigshospitalet). Data collection will continue until 2040 to assess long-term outcomes.\n\nThis study may help determine whether EUS-RFA can serve as a safe and effective alternative to traditional surgery for selected patients with small hormone-producing or benign tumors in the pancreas or adrenal glands, potentially reducing surgical risks and improving recovery and quality of life.",[74,75,29,76,77,78],"Insulinoma; Pancreas","MEN1","Radiofrequency Ablation","Endoscopic Ultrasound (EUS)","Conn Syndrome","2025-11-26",{"date":81,"type":52},"2025-12-09",{"date":83,"type":52},"2025-11-01",{"date":85,"type":22},"2041-12-31",{"name":87,"class":88},"Herlev Hospital","OTHER",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":114,"leadSponsor":116,"locationsCount":89},"100613282","effect-of-ofa-osa-versus-opioid-based-anesthesia-on-nets-and-cancer-cell-malignancy-after-colorectal-cancer-surgery-100613282","NCT07264556","Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer Surgery","Effect of Opioid-Free, Opioid-sparing Versus Opioid-based Anesthesia on Perioperative NETs and Cancer Cell Malignancy in Patients Undergoing Surgery for Colorectal Cancer: A Randomized, Controlled Trial","Inclusion Criteria:\n\n* aged 18-80 years old,\n* American Society of Anesthesiologists physical status I-III,\n* elective colorectal cancer surgery under general anesthesia\n\nExclusion Criteria:\n\n* previous history of colorectal surgery,\n* addicted to opioids,\n* serious major mental or physical illness (heart, pulmonary, hepatic, or renal diseases),\n* radiotherapy or chemotherapy history within 8 weeks prior to the surgery,\n* contraindications to anesthetic agents or epidural.","80 Years",{"count":99,"type":22},90,[101],"NA","Adult patients aged 18-80 years old, American Society of Anesthesiologists physical status I-III, who were scheduled for elective colorectal cancer surgery under general anesthesia were recruited for this study. They were randomized to receive opioid-free anesthesia (OFA), opioid-sparing anesthesia (OSA) and opioid-based anesthesia (OA) group.\n\nBlood samples were collected pre-surgery and 24h post-surgery. As primary endpoint, serum neutrophil myeloperoxidase (MPO) and citrullinated histone3 (CitH3) was measured. The secondary endpoints included the effects of postoperative serum on colorectal cancer (CRC) cells malignancy, numerical rating scale (NRS) scores, postoperative adverse events and recovery profiles.\n\nFor OA group, intraoperative remifentanil and sufentanil were used and postoperative patient controlled intravenous analgesia (PCIA) was performed with 0.5μg\u002Fml of sufentanil and 0.75 mg\u002FmL flurbiprofen, and the PCIA was stopped 48 h after surgery.\n\nFor OSA group, remifentanil and sufentanil were used only for anesthetic induction and the patient received ultrasound-guided transversus abdominis plane (TAP) nerve blockwas performed. Patient controlled intravenous analgesia (PCIA) was performed with 1mg\u002FmL of oxycodone and 0.75 mg\u002FmL flurbiprofen after surgery, and the PCIA was stopped 48 hours after surgery.\n\nFor OFA group, intraoperative epidural anesthesia combined with general anesthesia was used, and esketamine, lidocaine and dexmedetomidine for analgesia. Patient controlled epidural analgesia (PCEA) was used and terminated 48 hours after surgery.",[104,105,29],"Colorectal Cancer","Opioid-free Anesthesia",[107,108,109],"Opioid free anesthesia","Neutrophil extracellular trapping markers","colorectal cancer","2025-11-24",{"date":112,"type":52},"2025-12-04",{"date":83,"type":52},{"date":115,"type":22},"2025-12-15",{"name":117,"class":88},"Fudan University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":48,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":89},"100564721","early-phase-1-a-dual-targeting-tracer-tate-rgd-for-the-diagnosis-of-sstr--and-rgd--positive-tumors-100564721","NCT06632860","A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors","a Novel Dual-Targeting Molecular Probe TATE-RGD for the Diagnostic Integration of SSTR2 and αvβ3 Positive Tumors","Inclusion Criteria:\n\n* histologically confirmed various cancer patients;\n* 68Ga-TATE-RGD and 18F-FDG PET\u002FCT within a week;\n* signed written consent.\n\nExclusion Criteria:\n\n* known allergy against TATE-RGD;\n* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.","90 Years",{"count":127,"type":22},40,[129],"EARLY_PHASE1","The US FDA approved a targeted somatostatin receptor 2 imaging agent, 68Ga-DOTATATE, in 2016. It has higher uptake in small cell lung cancer, pulmonary carcinoid, and medullary thyroid cancer. Integrin αvβ3 is highly expressed in some tumor cells and new blood vessels, making it an ideal target for targeted diagnosis and treatment of tumors and tumor vessels.68Ga-labeled DOTA-TATE-RGD is a new type of tumor-specific imaging agent developed by researchers based on the above foundation, which is used for targeted diagnosis and internal radiation therapy for patients with SSTR2 and αvβ3 positive tumors.",[132,133,29],"Iodine-resistant Thyroid Cancer","Meningioma","2025-07-08",{"date":136,"type":52},"2025-07-09",{"date":138,"type":52},"2024-08-01",{"date":140,"type":22},"2025-12-30",{"name":142,"class":88},"Peking Union Medical College Hospital"]